Gastroenteritis, Viral

Tekijä Orenstein, Robert
Julkaisussa Encyclopedia of Gastroenterology (2020)

Clinical Pearls in Infectious Diseases

Tekijä Orenstein, Robert, Litin, Scott C.
Julkaistu 2010

Clostridioides difficile therapeutics: guidelines and beyond

Tekijä Orenstein, Robert, Patron, Roberto L.
Julkaisussa Ther Adv Infect Dis (2019)

1657 Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH CD Study

Tekijä Orenstein, Robert, Dubberke, Erik, Griesbach, Cheryl, Sobcinski, Mary Kay
Julkaisussa Open Forum Infect Dis (2014)

468 RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

Tekijä Dubberke, Erik, Orenstein, Robert, Mariani, Paul, Mullane, Kathleen, Sobcinski, Mary Kay
Julkaisussa Open Forum Infect Dis (2014)

1799 Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antiobiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study

Tekijä Mariani, Paul, Price, Connie S., Orenstein, Robert, Harris, Hill, Sobcinski, Mary Kay
Julkaisussa Open Forum Infect Dis (2014)

Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility

Tekijä Seto, Charlie T, Jeraldo, Patricio, Orenstein, Robert, Chia, Nicholas, DiBaise, John K
Julkaisussa Microbiome (2014)

Erratum to: Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility

Tekijä Seto, Charlie T., Jeraldo, Patricio, Orenstein, Robert, Chia, Nicholas, DiBaise, John K.
Julkaisussa Microbiome (2016)

Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis

Tekijä Tariq, Raseen, Cho, Janice, Kapoor, Saloni, Orenstein, Robert, Singh, Siddharth, Pardi, Darrell, Khanna, Sahil
Julkaisussa Open Forum Infect Dis (2017)

Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis

Tekijä Tariq, Raseen, Laguio-Vila, Maryrose, Tahir, Muhammad Waqas, Orenstein, Robert, Pardi, Darrell S., Khanna, Sahil
Julkaisussa Therap Adv Gastroenterol (2021)

Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009

Tekijä Olson, Timothy C, Bongartz, Tim, Crowson, Cynthia S, Roberts, Glenn D, Orenstein, Robert, Matteson, Eric L
Julkaistu 2011

Research Response to SARS-CoV-2/COVID-19

Tekijä Burger, Charles D., Mikhail, Amanda E., Orenstein, Robert, Ebbert, Jon O., Vergidis, Paschalis, Badley, Andrew D.
Julkaisussa Mayo Clin Proc (2020)

1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study

Tekijä Mische, Sarah, Orenstein, Robert, Dubberke, Erik R, Khanna, Sahil, Hecht, Gail, Dupont, Herbert, Lee, Christine, Blount, Ken
Julkaisussa Open Forum Infect Dis (2018)

The Epidemiology of Community-acquired Clostridium difficile infection: A population-based study

Tekijä Khanna, Sahil, Pardi, Darrell S., Aronson, Scott L., Kammer, Patricia P., Orenstein, Robert, St. Sauver, Jennifer L., Harmsen, W. Scott, Zinsmeister, Alan R.
Julkaistu 2011

Characteristics of Patients with Mild to Moderate Primary Pulmonary Coccidioidomycosis

Tekijä Blair, Janis E., Chang, Yu-Hui H., Cheng, Meng-Ru, Vaszar, Laszlo T., Vikram, Holenarasipur R., Orenstein, Robert, Kusne, Shimon, Ho, Stanford, Seville, Maria T., Parish, James M.
Julkaistu 2014

LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for...

Tekijä Orenstein, Robert, Mische, Sarah, Mische, Sarah, Blount, Ken, Blount, Ken, Bancke, Lindy, Su, Xin, Walsh, Dana, Harvey, Adam, Gonzalez, Carlos, Gerding, Dale N, Gerding, Dale N
Julkaisussa Open Forum Infect Dis (2019)

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

Tekijä Temesgen, Zelalem, Burger, Charles D., Baker, Jason, Polk, Christopher, Libertin, Claudia, Kelley, Colleen, Marconi, Vincent C., Orenstein, Robert, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew D.
Julkaisussa medRxiv (2021)

Mild to moderate COVID-19 illness in adult outpatients: Characteristics, symptoms, and outcomes in the first 4 weeks of illness

Tekijä Blair, Janis E., Gotimukul, Ashwini, Wang, Fangfang, Mina, Syeda A., Bartels, Helen C., Burns, Mark W., Kole, Amy E., Vikram, Holenarasipur R., Gea-Banacloche, Juan C., Seville, M. Teresa, Petty, Skye A. Buckner, Vikram, Avinash, Orenstein, Robert
Julkaisussa Medicine (Baltimore) (2021)

First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia

Tekijä Temesgen, Zelalem, Assi, Mariam, Vergidis, Paschalis, Rizza, Stacey A., Bauer, Philippe R., Pickering, Brian W., Razonable, Raymund R., Libertin, Claudia R., Burger, Charles D., Orenstein, Robert, Vargas, Hugo E., Varatharaj Palraj, Bharath Raj, Dababneh, Ala S., Chappell, Gabrielle, Chappell, Dale, Ahmed, Omar, Sakemura, Reona, Durrant, Cameron, Kenderian, Saad S., Badley, Andrew
Julkaisussa medRxiv (2020)

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study

Tekijä Temesgen, Zelalem, Assi, Mariam, Shweta, F.N.U., Vergidis, Paschalis, Rizza, Stacey A., Bauer, Philippe R., Pickering, Brian W., Razonable, Raymund R., Libertin, Claudia R., Burger, Charles D., Orenstein, Robert, Vargas, Hugo E., Palraj, Raj, Dababneh, Ala S., Chappell, Gabrielle, Chappell, Dale, Ahmed, Omar, Sakemura, Reona, Durrant, Cameron, Kenderian, Saad S., Badley, Andrew D.
Julkaisussa Mayo Clin Proc (2020)